Abstract 554MO
Background
The TRICE study was designed to determine whether intensifying the chemotherapy backbone in cetuximab-containing regimens could confer additional clinical benefits to RAS wild-type colorectal cancer (CRC) patients with initially unresectable liver metastases.
Methods
Patients were randomly assigned to receive either cetuximab plus FOLFOXIRI (triplet arm) or cetuximab plus FOLFOX (doublet arm) every 2 weeks. Primary efficacy analyses were conducted based on the intention-to-treat population, while safety analyses were performed on patients who received at least one line of chemotherapy. The primary end point was the objective response rate (ORR). Secondary end points included the median depth of tumor response (DpR), early tumor shrinkage (ETS), R0 resection rate, progression-free survival (PFS), overall survival (OS), and treatment-related adverse events.
Results
From January 2018 to December 2022, 146 patients were randomized to the cetuximab plus FOLFOXIRI (n = 72) or the cetuximab plus FOLFOX (n = 74) treatment arms. The ORR was comparable with 84.7% versus 79.7% in the triplet and doublet arms, respectively (OR = 0.71, 95% CI 0.30 to 1.67; P = .43). Although intensifying the chemotherapy backbone led to a higher median DpR (59.6% vs. 55.0%; P = .039), other secondary outcomes remained comparable between the two arms. At a median follow-up of 26.2 months, the median PFS was 11.7 months in the triplet arm vs. 13.4 months in the doublet arm (HR = 1.37, 95% CI 0.91 to 2.07; P = .13). Additionally, the triplet arm was associated with a higher incidence of grade 3-4 neutropenia (44.1% vs. 27.0%; P = .03) and diarrhea (5.9% vs. 0%; P = .03).
Conclusions
Although intensifying upfront systemic chemotherapy in RAS wild-type metastatic CRC patients offered a better depth of tumor response, there was an increase in neutropenia and diarrhea incidence with no significant difference in ORR, PFS, and R0 resection rate.
Clinical trial identification
NCT03493048.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
560MO - Maintenance with 5FU/LV-Aflibercept after induction with FOLFIRI-Aflibercept vs FOLFIRI-Aflibercept until progression in older patients (pts) in 2nd line metastatic colorectal cancer (mCRC): The randomized AFEMA trial
Presenter: Pilar García Alfonso
Session: Mini oral session - Gastrointestinal tumours, lower digestive
Resources:
Abstract
Slides
Webcast
Invited Discussant 558MO, 559MO and 560MO
Presenter: Jeanne Tie
Session: Mini oral session - Gastrointestinal tumours, lower digestive
Resources:
Slides
Webcast